Pharma: Other News To Note
Thursday, October 11, 2012
Almirall SA, of Barcelona, Spain, said it granted Invida Holdings Private Ltd., part of the Menarini Group, of Florence, Italy, the commercial rights for Aclidinium, a long-acting inhaled muscarinic antagonist, in Australia and New Zealand, for chronic obstructive pulmonary disorder.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.